# Catalent, Inc.  Share Price Target ‘$58.30’, now 1.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/catalent-inc.share-price-target-58.30-now-1.5-upside-potential/4121164701
- Published: 2024-07-12T15:17:26+01:00
- Author: Charlotte Edwards

**Catalent, Inc.** with ticker code (CTLT) now have 10 analysts in total covering
the stock. The consensus rating is pointing to ‘hold’. The target price High/Low
ranges between $63.50 and $42.00 with the average share target price sitting at 
$58.30. (at the time of writing). Given that the stocks previous close was at $57.43
this now indicates there is a potential upside of 1.5%. The day 50 moving average
is $55.75 and the 200 day MA is $50.25. The total market capitalization for the 
company now stands at 10.51B. The stock price for the company is currently $58.07
USD

 The potential market cap would be $10,668,715,860 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $22.75 and
a -0.71% return on assets.

Catalent, Inc. is a provider of development and manufacturing solutions for drug,
cell and gene therapies biologics, vaccines, and consumer health products. The Company’s
segments include Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery,
and Clinical Supply Services. Its Biologics segment provides development and manufacturing
for protein, plasmid DNA mRNA, cell therapy, viral vaccines and viral-based gene
therapies. Its Softgel and Oral Technologies segment provide formulation, development,
and manufacturing services for soft capsules, as well as large-scale manufacturing
of oral solid dose forms. Its Oral and Specialty Delivery segment provides formulation
development and manufacturing across a range of technologies along with integrated
downstream clinical development and commercial supply solutions. Its Clinical Supply
Services segment provides manufacturing, packaging, storage, distribution, and inventory
management for, drugs, biologics and clinical trials.

Share on: